Experts flag eye inflammation reports tied to Apellis' geographic atrophy med Syfovre

Apellis Pharmaceuticals' Syfovre, after achieving the first FDA approval for advanced eye disease geographic atrophy, has been associated with rare but severe side effects, according to the American Society of Retinal Specialists (ASRS).